Quick Overview.
Ostarine (also known as MK-2866 or Enobosarm) is a Selective Androgen Receptor Modulator (SARM). It was originally developed by GTx Inc. to treat muscle wasting diseases and osteoporosis. In the fitness and biohacking communities, it is widely considered the "beginner's SARM" because it is the most thoroughly researched, the mildest, and the most well-tolerated of all SARMs.[1][2]
Unlike traditional anabolic steroids (like testosterone), which flood the entire body and affect every organ, SARMs are designed to be "selective." They are engineered to bind specifically to the androgen receptors in muscle and bone tissue, while largely ignoring the receptors in the prostate, heart, and hairline. Ostarine tells your body to build muscle and preserve bone without causing the severe side effects associated with steroids.[3]
- Primary Use Case: Lean muscle preservation during a caloric deficit (cutting), mild muscle gain, and joint/tendon healing.
- Mechanism: Selective agonism of the androgen receptor in skeletal muscle and bone.[4]
- Who it is for: Beginners looking for a mild introduction to performance enhancement, or athletes looking to preserve muscle while losing fat.
- Who it is NOT for: Anyone expecting massive, steroid-like muscle gains, or tested athletes (it is highly detectable).
Turn this protocol into your actual schedule.
Log every dose, every side-effect, and every PR on one timeline.
The Protocol & Usage Guide.
confidence_tier: well-established
Ostarine is highly bioavailable orally, meaning it is taken as a liquid or pill, not injected. Because it has a half-life of approximately 24 hours, it only needs to be dosed once per day.[5]
Standard Dosing Schedule
| Phase | Dose | Frequency | Timing |
|---|---|---|---|
| Beginner / Cutting | 10 mg to 15 mg | Daily | Morning, with or without food |
| Intermediate / Recomp | 20 mg | Daily | Morning, with or without food |
| Advanced / Bulking | 25 mg to 30 mg | Daily | Morning, with or without food |
| Women | 5 mg to 10 mg | Daily | Morning, with or without food |
Cycle Length & Discontinuation Protocol
- Cycle Length: 8 to 12 weeks. Do not exceed 12 weeks to prevent severe testosterone suppression and liver stress.
- Discontinuation (PCT): Despite claims that Ostarine is "non-suppressive," bloodwork consistently shows that doses above 10mg will suppress natural testosterone production. A mild Post Cycle Therapy (PCT) using a SERM like Enclomiphene (6.25mg daily for 2-4 weeks) or Nolvadex (10-20mg daily for 4 weeks) is highly recommended.
Nutritional Support & Recommended Supplements.
confidence_tier: well-established
| Supplement | Rationale | Recommended Dose |
|---|---|---|
| NAC or TUDCA | Ostarine is processed by the liver. While milder than oral steroids, it still causes mild liver stress. Liver support is mandatory. | NAC: 1200mg daily. TUDCA: 500mg daily. |
| Citrus Bergamot | SARMs are notorious for crushing HDL (good cholesterol) and spiking LDL (bad cholesterol). | 500-1000mg daily. |
| Omega-3 Fish Oil | Additional cardiovascular and lipid support. | 3-4g daily. |
Safety, Interactions & Side Effect Management.
confidence_tier: well-established
Side Effect Profile
| Side Effect | Severity | Frequency | Management |
|---|---|---|---|
| Testosterone Suppression | Moderate | Very Common | Use a SERM for PCT after the cycle. |
| Lipid Skew (Low HDL) | Moderate | Very Common | Supplement with Citrus Bergamot and Omega-3s. Do cardio. |
| Liver Enzyme Elevation | Mild/Moderate | Common | Use NAC or TUDCA. Avoid alcohol completely during the cycle. |
| Headaches / Nausea | Mild | Occasional | Usually subsides after the first week. Ensure adequate hydration. |
Contraindications
- Absolute: Individuals with pre-existing liver disease or severe cardiovascular issues.
- Absolute: Teenagers whose endocrine systems are still developing.
Drug Interactions
- Alcohol: Severe. Combining oral SARMs with alcohol places immense stress on the liver.
- Accutane / Hepatotoxic Drugs: Severe. Do not stack with other liver-toxic medications.
Common Stacks & Combinations.
confidence_tier: community
| Stack | Goal | Rationale |
|---|---|---|
| Ostarine + Cardarine | The Ultimate Cutting Stack | Ostarine preserves the muscle while in a caloric deficit; Cardarine (GW-501516) drastically increases endurance and fat oxidation. |
| Ostarine + Enclomiphene | SARM+SERM Cycle | Taking a low dose of Enclomiphene (6.25mg) during the Ostarine cycle prevents testosterone suppression, keeping energy and libido high. |
Body Composition & Training Guide.
confidence_tier: community
- The "Recomp" King: Ostarine shines in a body recomposition phase (eating at maintenance calories). Users frequently report losing 2-3 lbs of fat while simultaneously gaining 2-3 lbs of muscle over an 8-week cycle.
- Joint Healing: Anecdotally, Ostarine is famous for its ability to heal nagging joint and tendon injuries. Many powerlifters use low doses (10mg) specifically to recover from shoulder or knee pain.
- Expectation Management: Ostarine will not make you look like a professional bodybuilder. The gains are very "dry" (no water retention) and modest. Expect 3-5 lbs of retainable muscle tissue per cycle.
Storage, Handling & Accessibility.
confidence_tier: well-established
- Storage: Store liquid solutions or capsules at room temperature in a cool, dark place.
- WADA Status: Banned in competitive sports under section S1.2 (Other Anabolic Agents). It is highly detectable in urine for weeks after discontinuation.
- Cost & Accessibility: Widely available from research chemical vendors as a "research chemical not for human consumption." Typically costs $40-$60 for a 30mL bottle (usually dosed at 25mg/mL).
Bloodwork Monitoring Guide.
confidence_tier: well-established
| Biomarker | When to Test | Why it Matters |
|---|---|---|
| Total & Free Testosterone | Baseline, Post-Cycle | To measure the degree of suppression and determine if PCT is required. |
| AST / ALT (Liver) | Baseline, Mid-Cycle | To ensure the liver is processing the compound safely. |
| Lipid Panel (HDL/LDL) | Baseline, Post-Cycle | SARMs reliably crash HDL. You must ensure it recovers post-cycle. |
Comparison to Similar Compounds.
confidence_tier: well-established
| Feature | Ostarine (MK-2866) | LGD-4033 (Ligandrol) | RAD-140 (Testolone) |
|---|---|---|---|
| Primary Goal | Cutting / Recomp | Bulking / Mass | Strength / Dry Mass |
| Potency | Mild | Strong | Very Strong |
| Suppression | Mild to Moderate | Severe | Severe |
| Water Retention | None | Moderate | None |
Deep Dive (For Advanced Researchers).
confidence_tier: well-established
Mechanism of Action
Enobosarm (Ostarine) is a non-steroidal selective androgen receptor modulator. It binds to the androgen receptor (AR) with high affinity (Ki = 3.8 nM) and acts as a full agonist in muscle and bone tissue, but exhibits only weak, partial agonism in the prostate and seminal vesicles.[6]
Cellular Pathways
- Anabolic Selectivity: The exact mechanism of tissue selectivity is not fully understood, but it is believed to involve ligand-specific conformational changes in the AR that recruit different co-activators or co-repressors depending on the cellular environment (muscle vs. prostate).[7]
- Bone Mineral Density: In preclinical models, Ostarine has been shown to increase bone volume and density, making it a prime candidate for osteoporosis treatment. It stimulates osteoblast activity while inhibiting osteoclast differentiation.[8]
Clinical Trial Summary
Ostarine is the most clinically evaluated SARM in existence, having undergone multiple Phase I, II, and III trials.
- Phase II Muscle Wasting Trial: A 12-week, double-blind, placebo-controlled trial in 120 healthy elderly men and women showed that 3mg of Ostarine daily significantly increased lean body mass (LBM) and improved physical function (stair climb power) with no androgenic side effects.[9]
- Cancer Cachexia (POWER Trials): Phase III trials evaluated Ostarine for the prevention of muscle wasting in non-small cell lung cancer patients. While it successfully increased LBM, it narrowly missed its primary endpoint for physical function improvement, halting its FDA approval process.[10]
Synergy & Antagonism Analysis
- Hepatotoxicity: While clinical trials at 3mg showed no liver toxicity, the bodybuilding community uses doses 10x higher (20-30mg). At these doses, drug-induced liver injury (DILI) is a documented risk. Several case reports in medical literature detail cholestatic liver injury in young men using high-dose Ostarine.[11][12]
Frequently Asked Questions (FAQ).
confidence_tier: community
Q: Do I really need a PCT for Ostarine? A: Yes. While 3mg in clinical trials did not cause severe suppression, the 20mg+ doses used for bodybuilding absolutely will suppress your natural testosterone. Bloodwork confirms this universally. Have Enclomiphene or Nolvadex on hand.
Q: Can women use Ostarine? A: Yes. Because it is highly selective and lacks the virilizing properties of steroids (like voice deepening or facial hair growth), it is the most popular SARM for female athletes. Doses should be kept low (5-10mg).
Q: Is it a steroid? A: No. Steroids have a specific 4-ring carbon structure. Ostarine is a non-steroidal compound. However, it acts on the exact same receptors as steroids.
Q: Will I lose my gains when I stop? A: If you run a proper PCT, continue training hard, and eat enough protein, you should keep the vast majority of the muscle tissue built on Ostarine.
International Regulatory Status.
confidence_tier: well-established
| Agency | Status | Notes |
|---|---|---|
| US FDA | Investigational | Not approved for human consumption. Sold legally only as a "research chemical." |
| WADA | Banned | Prohibited at all times under S1.2. |
| UK MHRA | Unlicensed | Illegal to sell as a food supplement; legal to possess for research. |
| EU EMA | Unlicensed | Not approved for medical use. |
Decision Tree.
confidence_tier: community
[Goal: Build Muscle / Lose Fat with SARMs?]
|
+-- Are you a beginner to performance-enhancing drugs?
|
+-- (No) -> Consider LGD-4033 or RAD-140 for greater mass.
|
+-- (Yes) -> Ostarine is the safest starting point.
|
+-- Take 15-20mg daily for 8 weeks.
+-- Take Liver Support (NAC) daily.
+-- Follow with 2-4 weeks of Enclomiphene (PCT).Schema.org Data.
{
"@context": "https://schema.org",
"@type": "MedicalEntity",
"name": "Ostarine",
"alternateName": ["MK-2866", "Enobosarm", "GTx-024"],
"description": "A non-steroidal selective androgen receptor modulator (SARM) investigated for the treatment of muscle wasting and osteoporosis, widely used off-label for muscle preservation and growth.",
"legalStatus": {
"@type": "DrugLegalStatus",
"description": "Investigational new drug. Not FDA approved. Banned by WADA."
}
}What we cited.
- Narayanan R, et al. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008;6:e010. doi:10.1621/nrs.06010
- Dalton JT, et al. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun. 1998;244(1):1-4. doi:10.1006/bbrc.1998.8203
- Yin D, et al. Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther. 2003;304(3):1334-1340. doi:10.1124/jpet.102.040840
- Bhasin S, et al. Selective androgen receptor modulators (SARMs) as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009;12(3):232-240. doi:10.1097/MCO.0b013e32832a3d79
- Coss CC, et al. Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian J Androl. 2014;16(2):256-261. doi:10.4103/1008-682X.122338
- Gao W, et al. Chemistry and structural biology of androgen receptor. Chem Rev. 2005;105(9):3352-3370. doi:10.1021/cr020456u
- Mohler ML, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009;52(10):3597-3617. doi:10.1021/jm900280m
- Kearbey JD, et al. Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide in rats and dogs. Xenobiotica. 2004;34(3):273-280. doi:10.1080/00498250410001662920
- Dobs AS, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335-345. doi:10.1016/S1470-2045(13)70055-X
- Crawford J, et al. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep. 2016;18(6):37. doi:10.1007/s11912-016-0522-0
- Koller T, et al. Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator. ACG Case Rep J. 2021;8(1):e00519. doi:10.14309/crj.0000000000000519
- Leciejewska N, et al. Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: analysis of suspected cases. Eur J Clin Pharmacol. 2024;80(3):421-430. doi:10.1007/s00228-023-03592-3